|

roginolisib Clinical Trials

3 actively recruiting trials across 1 location

Also known as: MSC2360844A, [6-fluoro-1-(4-morpholin-4-ylmethyl-phenyl)-5,5-dioxo-4,5-dihydro-1H-5λ6-thiochro-meno[4,3-c]pyrazol-3-yl]-morpholin-4-yl-methanone hemi-fumarate, C26 H27 F N4 O5 S. 0.5 C4H4O4

Pipeline

Phase 1: 1Phase 1/2: 2

Top Sponsors

  • The Lymphoma Academic Research Organisation1
  • St Vincent's Hospital, Sydney1
  • Jennifer R. Brown, MD, PhD1

Indications

  • Cancer3
  • Uveal Melanoma, Metastatic1
  • Relapsed Leukemia1
  • Relapsed Cancer1
  • Peripheral T Cells Lymphoma (PTCL)1

Other2 trials

A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas
Phase 1/2
Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis
Phase 1

Boston, Massachusetts1 trial

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

Dana-Farber Cancer Institute

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.